

# **Journal Club:**

# Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

by I.Tirosh, B.Izar et al. in *Science, 2016* 

Petr Nazarov

2018-05-22



### Variants

#### f-scLVM: scalable and versatile factor analysis for single-cell RNA-seq

Florian Buettner<sup>1,6\*</sup>, Naruemon Pratanwanich<sup>1</sup>, Davis J. McCarthy<sup>1,2</sup>, John C. Marioni<sup>1,3,4\*</sup> and Oliver Stegle<sup>1,5\*</sup>



# Bias, robustness and scalability in single-cell differential expression analysis

Charlotte Soneson<sup>1,2</sup> & Mark D Robinson<sup>1,2</sup>

( CrossMark







### **RESEARCH ARTICLES**

#### CANCER GENOMICS

# **Dissecting the multicellular** ecosystem of metastatic melanoma by single-cell RNA-seq

Itay Tirosh,<sup>1\*</sup> Benjamin Izar,<sup>1,2,3\*</sup>†‡ Sanjay M. Prakadan,<sup>1,4,5,6</sup> Marc H. Wadsworth II,<sup>1,4,5,6</sup> Daniel Treacy,<sup>1</sup> John J. Trombetta,<sup>1</sup> Asaf Rotem,<sup>1,2,3</sup> Christopher Rodman,<sup>1</sup> Christine Lian,<sup>7</sup> George Murphy,<sup>7</sup> Mohammad Fallahi-Sichani,<sup>8</sup> Ken Dutton-Regester,<sup>1,2,9</sup> Jia-Ren Lin,<sup>10</sup> Ofir Cohen,<sup>1</sup> Parin Shah,<sup>2</sup> Diana Lu,<sup>1</sup> challenesinel hoterestinel Alex S. Genshaft,<sup>1,4,5,6</sup> Travis K. Hughes,<sup>1,4,6,11</sup> Carly G. K. Ziegler,<sup>1,4,6,11</sup> Samuel W. Kazer, <sup>1,4,5,6</sup> Aleth Gaillard, <sup>1,4,5,6</sup> Kellie E. Kolb, <sup>1,4,5,6</sup> Alexandra-Chloé Villani,<sup>1</sup> Cory M. Johannessen,<sup>1</sup> Aleksandr Y. Andreev,<sup>1</sup> Eliezer M. Van Allen,<sup>1,2,3</sup> Monica Bertagnolli,<sup>12,13</sup> Peter K. Sorger,<sup>8,10,14</sup> Ryan J. Sullivan,<sup>15</sup> Keith T. Flaherty,<sup>15</sup> Dennie T. Frederick,<sup>15</sup> Judit Jané-Valbuena,<sup>1</sup> Charles H. Yoon,<sup>12,13</sup><sup>†</sup> Orit Rozenblatt-Rosen,<sup>1</sup><sup>†</sup> Alex K. Shalek,<sup>1,4,5,6,11,16</sup><sup>†</sup> Aviv Regev, 1,17,18 + Levi A. Garraway 1,2,3,14 + +



Only 25% of tumors originate from nevi (moles)!

#### **Properties:**

- Rapid progression
- > Early metastasis
- Highest mutation load
- Immune response +/-
- > 5-year survival:
  - ➢ 98% when primary
  - ➢ 17% after spread

Age-standardized new cases per year



## Melanoma

### Reminder







## Experiment

#### Sample collection & sorting

- Fresh tumors (45 min to cell suspension)
- Cell sorting: gated for viable cells
- Cell sorting separated viable cells to immune and non-immune by CD45



### Experiment

**Pipeline for RNA-seq** 

- Illumina NextSeq 500 instrument using 30bp paired-end reads
- Bowtie for mapping on UCSC hg19
- > Expression by RSEM using TPM:  $E = \log_2(TPM/10 + 1)$
- Exclude cells with less than 1700 genes detected or expression of housekeeping genes < 3</p>

$$\mathrm{TPM}_{i} = \frac{X_{i}}{\widetilde{l}_{i}} \cdot \left(\frac{1}{\sum_{j} \frac{X_{j}}{\widetilde{l}_{j}}}\right) \cdot 10^{6}$$



### **Cell Classification**

#### Malignant / Normal

CNV were estimated from sequencing data: moving average with limited standardized expression b/w -3, 3



SNV allowed separating malignant from non-malignant non-immune cells (CAF)



### **Cell Classification**

#### **Inter-tumor heterogeneity**



#### Tumor cells – patient specific. Non-malignant – similar b/w patients



#### **Heterogeneity in cell cycle**



- PC1 was linked to number of reads per sample
- PC2 was linked to cell cycle
- PC3,PC6 segregation treatment-naïve tumor from rest



Gene signature taken from literature resulted in G1/S and G2/M scores



Cell cycle status of cells can be identified. Tumors differ in the proliferation speed



#### **Heterogeneity in location**



These genes one are also generally coexpressed across melanoma tumors profiled in bulk in TCGA

Cancer cells from different locations express different genes. Interestingly – similar genes observed in immune cells





#### **Dormant drug-resistant subpopulation**

PC4-PC5 are highly correlated with MITF (master melanocyte tr. regulator and oncogene) Hypothesis: there <u>may be</u> dormant drug-resistant cells.

MITF **^** TYR, PMEL, MLANA

**MITF**  $\uparrow \downarrow$  AX L, NGFR: resistance to RAF/MEK inhibition that blocks proliferation, and activate apoptosis



2 programs. Intratumor heterogeneity was observed, suggesting presence of "dormant" cells



#### **Dormant drug-resistant subpopulation: test**

6 paired BRAF-mut melanoma biopsies before and after RAF/MEK inhibition: vemurafenib(1) and dabrafenib + trametinib(5).



#### After treatment, tumors become more "AXL-biased". AXL-program and MET mutually exclusive



## **Non-Malignant Cells**

#### **Types and environment**



### **Non-Malignant Cells**

#### Genes expressed by CAF are associated with T-cell abundance



LUXEMBOURG

RCH DEDICATED TO LIFE

INSTITUTE OF **HEALTH** 

> CCL19,CXCL12 - chemotactic (movement stimuli) PD-L2 – immune modulating C1S,C1R,C3,C4A,CFB,SERPING1 – complement

Complements the ability of antibodies and phagocytic cells to clear pathogens from an organism



Some genes, up-regulated in CAF, are also linked to higher percentage of T-cells – suggested to be an effect of stroma on immune cells.

A bit strange plot. Why sharp switch? Again – why genes are "calling for T-cells not vice versa – T-cells induce genes?





Α



#### T-cells: classification and exhaustion status

T cells can be classified and their exhaustion status measured

helper T cells (CD4+) cytotoxic T cells (CD8+) regulatory T cells (CD4+, CD25+, FOXP3+)

Signature of exhaustion

Stratify cells

DEA

**Enhanced signature** 



### **Non-Malignant Cells**

#### **T-cells exhaustion status**



Core exhaustion signature was determined across various tumors

Only 5 tumors considered, so "across various tumors" = "across 5 tumors"...



### **Non-Malignant Cells**



Expanded clones are depleted of non-exhausted cells and enriched for exhausted cells. scRNA-seq can characterize functionality of variable T cell populations.



### **Impact on Our Work**

#### **MelanomICA**



#### Highest correlation with ribosome related component and a technical component



### **Impact on Our Work**

#### **MelanomICA**



Top correlations were reasonable. But with low absolute value (perhaps can be improved)



### **Summary**

#### **And Comments**

- 1. Inter and intra-tumor heterogeneity is uncovered
  - tumors are different, stromal cells similar
  - spatial heterogeneity within the same tumor
  - presence of dormant resistant cells
- 2. Stromal CAF cells can influence proportion of T cells. Tumor cell composition is important!
- 3. Potential biomarkers are suggested for exhausted and cytotoxic T cells may help selecting patients for immune checkpoint blockade.



Authors used PCA and were quite lucky to see main effects. ICA would be better. Some ideas can be used for our work.

In general – I liked the paper. But some statements seems to be quite voluntaristic, esp. with tests used (t-test, permutation test, +/- adjustment, etc). Seems like selecting evidence that fit the theory.



### **Methods in Research**

#### **Classical vs "Modern" Scheme**



Only supporting evidences are published







### **Methods in Research**

#### Some Optimism in Wisdom of the Crowd



- Irreproducible results are less cited than reproducible
- > On average, like in Random Forest, we should go towards the **objective** ③